These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 9436954)

  • 41. Aminoglycosides: a practical review.
    Gonzalez LS; Spencer JP
    Am Fam Physician; 1998 Nov; 58(8):1811-20. PubMed ID: 9835856
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Extended-interval dosing of aminoglycosides.
    Blam ME; Hammer GS
    Mt Sinai J Med; 1997 Nov; 64(6):386-91. PubMed ID: 9364833
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extended dosage intervals for aminoglycosides.
    Rodman DP; Maxwell AJ; McKnight JT
    Am J Hosp Pharm; 1994 Aug; 51(16):2016-21. PubMed ID: 7977422
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Barriers to the effective management of respiratory tract infections in the community.
    Saginur R
    Infection; 2001 Dec; 29 Suppl 2():3-10. PubMed ID: 11785853
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies.
    Fish DN; Piscitelli SC; Danziger LH
    Pharmacotherapy; 1995; 15(3):279-91. PubMed ID: 7667163
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The evolution of aminoglycoside therapy: a single daily dose.
    Deamer RL; Dial LK
    Am Fam Physician; 1996 Apr; 53(5):1782-6. PubMed ID: 8623702
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Once-daily dosing regimen for aminoglycoside plus betalactam combination therapy of serious lower respiratory tract infections.
    Paradisi F; Corti G
    J Chemother; 1995 Aug; 7(4):338-43. PubMed ID: 8568544
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rational basis for the choice of regimens for empirical therapy of sepsis in granulocytopenic patients.
    Gaya H
    Clin Haematol; 1984 Oct; 13(3):573-86. PubMed ID: 6388933
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tigecycline: the answer to beta-lactam and fluoroquinolone resistance?
    Fraise AP
    J Infect; 2006 Nov; 53(5):293-300. PubMed ID: 16876253
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does antibiotic selection impact patient outcome?
    Harbarth S; Nobre V; Pittet D
    Clin Infect Dis; 2007 Jan; 44(1):87-93. PubMed ID: 17143822
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections.
    Joseph J; Rodvold KA
    Expert Opin Pharmacother; 2008 Mar; 9(4):561-75. PubMed ID: 18312158
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species.
    Rahal JJ
    Clin Infect Dis; 2006 Sep; 43 Suppl 2():S95-9. PubMed ID: 16894522
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmonary infections in patients without cystic fibrosis.
    Falagas ME; Kasiakou SK
    Infection; 2007 Feb; 35(1):3-10. PubMed ID: 17297582
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Back to the future: using aminoglycosides again and how to dose them optimally.
    Drusano GL; Ambrose PG; Bhavnani SM; Bertino JS; Nafziger AN; Louie A
    Clin Infect Dis; 2007 Sep; 45(6):753-60. PubMed ID: 17712761
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimal antibiotic dosing. The pharmacokinetic-pharmacodynamic interface.
    Reed MD
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):17-24. PubMed ID: 19667545
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses.
    Paul M; Leibovici L
    Infect Dis Clin North Am; 2009 Jun; 23(2):277-93. PubMed ID: 19393909
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Managing acute lower respiratory tract infections in an era of antibacterial resistance.
    Volturo GA; Low DE; Aghababian R
    Am J Emerg Med; 2006 May; 24(3):329-42. PubMed ID: 16635707
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Toxicologic and pharmacologic considerations in the choice of empiric parenteral antibiotics.
    Glauser MP; Neftel KA
    Am J Med; 1986 May; 80(5C):64-9. PubMed ID: 3717190
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Refractory respiratory tract infections. 4. Selection of chemotherapeutic agents and their administration. c. Pseudomonas infections].
    Oizumi K
    Nihon Rinsho; 1987 Mar; 45(3):526-30. PubMed ID: 3298728
    [No Abstract]   [Full Text] [Related]  

  • 60. [Enterococcal resistance to beta-lactam and aminoglycoside antibiotics].
    Liñares Louzao J; Ayats Ardite J; Alonso Figueres T
    Rev Clin Esp; 1995 Oct; 195 Suppl 4():16-21. PubMed ID: 9441311
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.